New York State Common Retirement Fund Sells 68,049 Shares of Amgen Inc. (NASDAQ:AMGN)

New York State Common Retirement Fund lessened its position in shares of Amgen Inc. (NASDAQ:AMGN) by 7.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 788,164 shares of the medical research company’s stock after selling 68,049 shares during the period. New York State Common Retirement Fund’s holdings in Amgen were worth $227,007,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Briaud Financial Planning Inc bought a new position in shares of Amgen in the 3rd quarter worth $26,000. BOK Financial Private Wealth Inc. bought a new position in shares of Amgen in the 4th quarter worth $29,000. OFI Invest Asset Management purchased a new stake in shares of Amgen in the 3rd quarter valued at $26,000. Planned Solutions Inc. purchased a new stake in shares of Amgen in the 4th quarter valued at $30,000. Finally, Providence Capital Advisors LLC purchased a new stake in shares of Amgen in the 3rd quarter valued at $30,000. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Up 1.1 %

NASDAQ:AMGN traded up $2.98 on Monday, reaching $271.91. 2,165,532 shares of the stock traded hands, compared to its average volume of 2,849,916. The company’s fifty day simple moving average is $276.90 and its 200 day simple moving average is $281.51. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 10.14. The company has a market capitalization of $145.85 billion, a price-to-earnings ratio of 21.53, a PEG ratio of 2.50 and a beta of 0.58. Amgen Inc. has a 12 month low of $211.71 and a 12 month high of $329.72.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. The firm had revenue of $8.20 billion for the quarter, compared to the consensus estimate of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same quarter last year, the firm posted $4.09 EPS. Equities analysts predict that Amgen Inc. will post 19.45 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be issued a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date is Thursday, May 16th. Amgen’s payout ratio is presently 72.06%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. SVB Leerink cut shares of Amgen from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $324.00 to $318.00 in a research note on Wednesday, February 7th. TD Cowen dropped their price target on shares of Amgen from $370.00 to $360.00 and set a “buy” rating for the company in a research report on Wednesday, April 17th. Raymond James began coverage on shares of Amgen in a research report on Thursday, March 28th. They set a “market perform” rating for the company. Truist Financial reissued a “buy” rating and set a $320.00 price target on shares of Amgen in a research report on Friday, April 12th. Finally, Leerink Partnrs cut shares of Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 7th. Ten investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $296.95.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.